New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:25 EDTISIS, ISISIsis Pharmaceuticals to host conference call
Conference call to discuss top-line ISIS-SMN Rx interim phase 2 results will be held on February 24 at 8:30 am. Webcast Link
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
17:31 EDTISISIsis Pharmaceuticals cuts stake in Regulus to 5.57%
Subscribe for More Information
July 29, 2015
17:13 EDTISISIsis announces publication of Phase 2 clinical results from volanesorsen study
Isis Pharmaceuticals and Akcea Therapeutics, its wholly owned subsidiary, announced that the New England Journal of Medicine has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen, formerly ISIS-APOCIIIRx, in patients with very high to severely high triglycerides. This publication follows the December 2014 publication in the New England Journal of Medicine of the positive Phase 2 results from a clinical study of volanesorsen in patients with familial chylomicronemia syndrome. Volanesorsen is part of Isis' lipid franchise, which is being developed and commercialized by Akcea Therapeutics.
July 27, 2015
10:40 EDTISISIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
07:07 EDTISISIsis Pharmaceuticals announces results from ISIS-TTRRx study
Subscribe for More Information
July 22, 2015
19:26 EDTISISIsis Pharmaceuticals announces positive clinical data of ISIS-APO(a)Rx published
Subscribe for More Information
July 21, 2015
07:13 EDTISISIsis Pharmaceuticals initiates Phase 1/2a clinical study of ISIS-HTT Rx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use